Stockscreener 앱 받기
1.53
1.92%
-0.03
시장 영업 전:
1.56
0.03
+1.96%
전일 마감가:
$1.56
열려 있는:
$1.5249
하루 거래량:
52,977
Relative Volume:
0.90
시가총액:
$15.07M
수익:
-
순이익/손실:
$-19.44M
주가수익비율:
-0.5755
EPS:
-2.6585
순현금흐름:
$-12.71M
1주 성능:
+3.38%
1개월 성능:
+8.51%
6개월 성능:
-27.14%
1년 성능:
-71.35%
1일 변동 폭
$1.52
$1.60
1주일 범위
$1.40
$1.61
52주 변동 폭
$1.17
$5.70
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.53 | 15.07M | 0 | -19.44M | -12.71M | -2.6585 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 76.72B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-18 | 개시 | Laidlaw | Buy |
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
Adicet Bio (NASDAQ: ACET) issues 250,000-share pre-funded warrant in exchange deal - Stock Titan
Climb Bio (CLYM) secures $110M private placement with institutional investors - Stock Titan
Passage Bio (NASDAQ: PASG) slashes workforce by 75% in 2026 restructuring - Stock Titan
BIO-key International, Inc. Files 8-K Report on Security Holder Vote Results – April 2026 - Minichart
Shareholders of Bio-Rad (NYSE: BIO) approve 2017 incentive plan changes - Stock Titan
BIO-key (NASDAQ: BKYI) wins approval for flexible reverse stock split - Stock Titan
CLYM News | CLIMB BIO INC (NASDAQ:CLYM) - ChartMill
Valion Bio (Nasdaq: TIVC) pivots to late-stage biopharma with Entolimod and CDMO - Stock Titan
Nasdaq warns BIO-key (NASDAQ: BKYI) after delayed 2025 Form 10-K - Stock Titan
CLYM (Climb Bio Inc.) rises 3.85 percent even as fourth quarter 2025 per share earnings miss analyst estimates.Sector Outperform - Xã Châu Thành
Intelligent Bio Solutions (NASDAQ: INBS) posts new investor deck and share update - Stock Titan
Strategic review at Passage Bio (NASDAQ: PASG) after FDA trial guidance - Stock Titan
Rese-cel data expands across autoimmune diseases at Cabaletta Bio (CABA) - Stock Titan
Nasdaq warns Mustang Bio (MBIO) on sub-$1 share price and listing risk - Stock Titan
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile - Yahoo Finance
CyPath Lung case study at bioAffinity (NASDAQ: BIAF) shows biopsy deferred - Stock Titan
Ibtrozi Prospects Asserts Nuvation Bio Inc. (NUVB) as one of the Best Healthcare Penny Stocks - Yahoo Finance
Bio Green Med Solution, Inc. Files Form 8-K with SEC – Company Details, Nasdaq Listing, and Contact Information (April 2026) - Minichart
Boundless Bio, Inc. Files Form 8-K with SEC – Corporate Details, Nasdaq Listing, and Emerging Growth Company Status - Minichart
Boundless Bio (NASDAQ: BOLD) pays $10M to exit long-term lab lease - Stock Titan
Analysts Remain Bullish on Gossamer Bio (GOSS) Despite Phase 3 Setback - Insider Monkey
Gossamer Bio, Inc. 8-K SEC Filing April 2026 – NASDAQ Listing, Company Details, and Compliance Information - Minichart
Kyntra Bio, Inc. Files 8-K Current Report with SEC – Company Information, Address, and NASDAQ Listing Details - Minichart
Annovis Bio (ANVS) launches $10M stock and warrant offering for Phase 3 drug - Stock Titan
Gossamer Bio Received Notice of Noncompliance - TradingView
Nasdaq warns Kyntra Bio (NASDAQ: FGEN) over Global Select listing test - Stock Titan
Nasdaq warns Gossamer Bio (NASDAQ: GOSS) over sub-$1 share price - Stock Titan
ImmunityBio (NASDAQ: IBRX) Q1 revenue jumps 168% to $44.2M - Stock Titan
Primrose Bio Function Generator™ Combinatorial Genetic Technology Case Study Published in PNAS - Morningstar
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 - ChartMill
[ARS] Passage BIO, Inc. SEC Filing - Stock Titan
8 Most Oversold Penny Stocks to Buy Right Now - Insider Monkey
Adaptin Bio shares approved for OTCQB quotation under ticker APTN; trading to begin in 6-8 weeks - TradingView
Adaptin Bio (APTN) wins OTCQB quotation and advances APTN-101 program - Stock Titan
ImmunityBio (NASDAQ: IBRX) outlines response to FDA ad concerns - Stock Titan
Climb Bio, Inc. 8-K Filing Details: Company Information, Address, and Stock Exchange Listing (April 2026) - Minichart
Director Michael Hoffman buys 713,800 Annovis Bio (ANVS) shares in open market - Stock Titan
Entera Bio (NASDAQ: ENTX) completes private placement with BVF funds - Stock Titan
Climb Bio (CLYM) consolidates CFO and principal accounting officer roles - Stock Titan
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Instil Bio (TIL) replaces Deloitte with RSM as independent auditor - Stock Titan
[144] Annovis Bio, Inc. SEC Filing - Stock Titan
Palisade Bio raises $3.0M from Iterative Health affiliate to support PALI-2108 Phase 2 enrollment - TradingView
Palisade Bio (NASDAQ: PALI) sells 1.54M shares to Iterative Health affiliate - Stock Titan
GOSS SEC FilingsGossamer Bio 10-K, 10-Q, 8-K Forms - Stock Titan
KALA SEC FilingsKala Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
APTN SEC FilingsAdaptin Bio 10-K, 10-Q, 8-K Forms - Stock Titan
Kala Bio (NASDAQ: KALA) notifies SEC of late 2025 10‑K, cites turnover - Stock Titan
LeonaBio (NASDAQ: ATHA) expands Sermonix deal disclosure and ELAINE-3 trial spend - Stock Titan
FGEN SEC FilingsFibrogen Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BIO SEC FilingsBio Rad Labs Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.00%
자본화:
|
볼륨(24시간):